Regarding the incidence of adverse events, compared with the EGFR-TKIs or chemotherapy alone group, the combination group showed a higher incidence of grade 3–4 leucopoenia, neutropenia, febrile neutropenia, anaemia, rash, fatigue and diarrhoea. The gene discussed is EGFR; the disease is neutropenia.